Quality Systems – Page 64

Design space poorly justified during comparability assessment – how to ensure smooth tech transfer

Managing Poorly Justified Design Space in Comparability Assessments for Effective Tech Transfer In the world of pharmaceutical manufacturing and quality assurance, the process of comparability assessments is crucial during tech…

Process knowledge not captured during scale-up – CAPA during development lifecycle

Understanding the Impact of Missing Process Knowledge During Scale-Up in Pharma Development In the pharmaceutical landscape, scale-up processes are critical for transitioning from laboratory to commercial production. However, the failure…

Scale-up risk not identified during scale-up – regulatory scrutiny implications

Identifying and Addressing Scale-Up Risks During Pharmaceutical Development In the pharmaceutical industry, the transition from laboratory-scale to commercial-scale manufacturing can convey various risks that, if unaddressed, may lead to regulatory…

Scale-up risk not identified during comparability assessment – regulatory scrutiny implications

Identifying Scale-Up Risks During Comparability Assessments to Avoid Regulatory Scrutiny In pharmaceutical manufacturing, the complexity of transitioning from lab-scale to commercial-scale production can introduce significant risks, particularly if not identified…

Process knowledge not captured during pilot scale – regulatory scrutiny implications

Implications of Uncaptured Process Knowledge During Pilot Scale for Regulatory Compliance In the competitive pharmaceutical landscape, maintaining stringent adherence to regulatory standards is paramount. A common pitfall occurs when critical…

Method development instability during scale-up – data package improvements for filing

“`html Addressing Method Development Challenges During Scale-Up: An Investigative Approach to Data Package Improvements Method development instability during scale-up can lead to significant challenges in pharmaceutical manufacturing, impacting product quality,…

Tech transfer readiness gaps during pilot scale – CAPA during development lifecycle

Identifying and Addressing Tech Transfer Readiness Gaps in Pilot Scale Development In the pharmaceutical industry, tech transfer readiness during pilot scale development is critical for ensuring a seamless transition between…

Design space poorly justified during pilot scale – CAPA during development lifecycle

Addressing Poor Justification of Design Space During the Pilot Scale: A Structured CAPA Approach The pharmaceutical industry often faces challenges related to design space justifications during the pilot scale of…

Design space poorly justified during scale-up – data package improvements for filing

“`html Enhancing Data Packages for Design Space Justification During Scale-Up In the pharmaceutical manufacturing landscape, a poorly justified design space during scale-up can spell trouble for compliance and market readiness.…

Process knowledge not captured during transfer to manufacturing – downstream GMP risk and prevention

Understanding the Risk of Uncaptured Process Knowledge in Manufacturing Transfers In the pharmaceutical industry, the transfer of process knowledge from research and development (R&D) to manufacturing is crucial for ensuring…

Design space poorly justified during pilot scale – downstream GMP risk and prevention

“`html Risk Management Strategies for Poorly Justified Design Space during Pilot Scale Operations In the pharmaceutical manufacturing landscape, pilot scale operations play a crucial role in bridging the gap between…

Excipient variability impact during transfer to manufacturing – how to ensure smooth tech transfer

“`html Understanding the Impact of Excipient Variability During Manufacturing Transfers Variability in excipients can significantly affect the quality and consistency of pharmaceutical products, particularly during the transfer from development to…